Cochrane · systematic review · CD012143
Direct‐acting antivirals for chronic hepatitis C
Jakobsen, JC, Nielsen, EE, Feinberg, J, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 66.7%Low 2 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyDirect‐acting antivirals versus control
Population: adults with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at maximum Direct‐acting antivirals vs control | OR 3.72 [0.53, 26.18] | 11 studies · 2996 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with one or more serious adverse event at maximum Direct‐acting antivirals vs control | OR 0.93 [0.75, 1.15] | 43 studies · 15817 participants | Very low Downgraded: risk of bias, indirectness |
Proportion of participants with no sustained virological response at maximum Direct‐acting antivirals vs control | RR 0.44 [0.37, 0.52] | 32 studies · 6886 participants | Low Downgraded: risk of bias |
Direct‐acting antivirals withdrawn from the market versus control
Population: adults with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at maximum Direct‐acting antivirals withdrawn from the market vs control | OR 0.64 [0.23, 1.79] | 5 studies · 3045 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with one or more serious adverse event at maximum Direct‐acting antivirals withdrawn from the market vs control | OR 1.45 [1.22, 1.73] | 29 studies · 9229 participants | Very low Downgraded: risk of bias, indirectness |
Proportion of participants with no sustained virological response at maximum Direct‐acting antivirals withdrawn from the market vs control | RR 0.61 [0.55, 0.69] | 21 studies · 9075 participants | Low Downgraded: risk of bias |
Direct‐acting antivirals versus control
Population: adults with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at maximum Direct‐acting antivirals vs control | OR 3.72 [0.53, 26.18] | 11 studies · 2996 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with one or more serious adverse event at maximum Direct‐acting antivirals vs control | OR 0.93 [0.75, 1.15] | 43 studies · 15817 participants | Very low Downgraded: risk of bias, indirectness |
Proportion of participants with no sustained virological response at maximum Direct‐acting antivirals vs control | RR 0.44 [0.37, 0.52] | 32 studies · 6886 participants | Very low Downgraded: risk of bias, indirectness |
Direct‐acting antivirals withdrawn from the market versus control
Population: adults with chronic hepatitis C
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at maximum Direct‐acting antivirals withdrawn from the market vs control | OR 0.64 [0.23, 1.79] | 5 studies · 3045 participants | Very low Downgraded: risk of bias, imprecision |
Proportion of participants with one or more serious adverse event at maximum Direct‐acting antivirals withdrawn from the market vs control | OR 1.45 [1.22, 1.73] | 29 studies · 9229 participants | Very low Downgraded: risk of bias, indirectness |
Proportion of participants with no sustained virological response at maximum Direct‐acting antivirals withdrawn from the market vs control | RR 0.61 [0.55, 0.69] | 21 studies · 9075 participants | Very low Downgraded: risk of bias, indirectness |